Oncology - Myeloproliferative Dz News & Articles

Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.

On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Patients 50+ may be at increased risk for pneumococcal disease. Learn what you can do.

Smartest Doc Challenge
MDLinx
Pediatric Oncology Clinical Pearls

D Scott Cunningham MD, PhD
Site Editor, MDLinx
Transition rates for adenomas to CRC

Jill Baker
MDLinx Career Center
New Jobs in Your Specialty

MDLinx Top Read
MDLinx
Are your journals collecting cobwebs?

MDLinx Conference Center
MDLinx
June Conference Calendar

New!	>> Find out who is the Smartest Doc in Oncology!

Articles

Latest (1) Full Text Articles (139) Focus on Hematology

Ranked, sorted, and summarized by MDLinx editors from the latest literature

Topics:

41 Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction Hematology, May 22, 2013 Clinical Article

42 Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma Full Text OncoTargets and Therapy, May 21, 2013 Review Article Clinical Article

43 Therapeutic enhancement of ER stress with Insulin Like Growth Factor 1 (IGF-1) sensitizes myeloma cells to proteasomal inhibitors Clinical Cancer Research, May 20, 2013 Clinical Article

44 Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy British Journal of Haematology, May 20, 2013 Clinical Article

45 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 20, 2013 Clinical Article

46 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 16, 2013 Clinical Article

47 IRF4 promotes cell proliferation by JNK pathway in multiple myeloma Medical Oncology, May 15, 2013 Clinical Article

48 A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease Clinical Cancer Research, May 14, 2013

49 In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Clinical Cancer Research, May 14, 2013 Clinical Article

50 Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma British Journal of Cancer, May 10, 2013 Clinical Article

51 TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity British Journal of Haematology, May 10, 2013 Clinical Article

52 Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales The European Journal of Health Economics, May 10, 2013 Clinical Article

53 CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Leukemia, May 9, 2013 Clinical Article

54 Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma Biology of Blood and Marrow Transplantation, May 9, 2013 Clinical Article

55 Reactive Oxygen Species-Mediated Activation of AMP-Activated Protein Kinase and c-Jun N-terminal Kinase Plays a Critical Role in Beta-Sitosterol-Induced Apoptosis in Multiple Myeloma U266 cells Phytotherapy Research, May 9, 2013 Clinical Article

56 Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution Full Text Haematologica, May 8, 2013 Clinical Article

57 Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma European Journal of Haematology, May 8, 2013 Clinical Article

58 Cellular immunotherapy for plasma cell myeloma Bone Marrow Transplantation, May 8, 2013 Clinical Article

59 Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study British Journal of Cancer, May 6, 2013

60 The Tumor Microenvironment: A Pitch for Multiple Players Frontiers in Oncology, May 6, 2013 Clinical Article

50 available pages First Previous 3 4 5 6 7 8 9 10 11 12 Next Last

Clinical Pearls in Oncology

The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease

» Test your knowledge. Take the Smartest Doc challenge today!

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.

Read the article summary

HCC risk increased in patients with AIDS

As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.

Read the article summary

RAB25 is a prognostic marker for ovarian cancer

As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment American Journal of Hematology, April 22, 2013

2 Body size in relation to incidence of subtypes of haematological malignancy in the prospective Million Women Study British Journal of Cancer, May 6, 2013

3 A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease Clinical Cancer Research, May 14, 2013

4 Personalized management of essential thrombocythemia—application of recent evidence to clinical practice Leukemia, May 3, 2013

5 Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review British Journal of Haematology, April 29, 2013 Review Article

6 Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma OncoTargets and Therapy, May 21, 2013 Free full text Review Article

7 United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma International Journal of Laboratory Hematology, May 1, 2013

8 Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction Hematology, May 22, 2013

9 D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma British Journal of Haematology, April 24, 2013

10 Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution Haematologica, May 8, 2013 Free full text

11 Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy International Journal of Hematology, April 26, 2013

12 Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy British Journal of Haematology, May 20, 2013

13 Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma British Journal of Cancer, May 10, 2013

14 Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales The European Journal of Health Economics, May 10, 2013

15 In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells Clinical Cancer Research, May 14, 2013

16 Lenalidomide in multiple myeloma—a practice guideline Current Oncology, April 23, 2013 Free full text

17 Very long lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment European Journal of Haematology, May 23, 2013

18 IRF4 promotes cell proliferation by JNK pathway in multiple myeloma Medical Oncology, May 15, 2013

19 GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells Hematology, May 16, 2013

20 Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction Hematology, May 29, 2013

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Oncology - Myeloproliferative Dz News & Articles

Articles

Clinical Pearls in Oncology

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

HCC risk increased in patients with AIDS

RAB25 is a prognostic marker for ovarian cancer

Most Popular Oncology Articles

Other Topics in Oncology